While large molecules continue to advance in drug development pipelines, small molecule Active Pharmaceutical Ingredients (APIs) still retain their historical dominance among new drug applications (NDAs). However, the last few years have seen the lines blurring between traditional chemical synthesis of small molecule APIs and biofermentation of large molecules, as production of small molecule drug substances in recombinant hosts gains ground. This is due to recent technological developments which have led to significant growth in the suitability of fermentation for a myriad of applications. In this white paper, the impact of the evolution of synthetic biology and supporting technologies on modern fermentation practices will be discussed.
Download our white paper to gain insights on:
- The Changing Landscape of Drug Development: Explore how fermentation is reshaping the pharmaceutical sector, bridging the gap between small molecule APIs and large molecule biofermentation.
- Advantages of Fermentation: Discover the benefits of fermentation, including the creation of novel molecules, flexible synthesis capabilities, sustainability, and cost-effectiveness.
- Technological Progress in Fermentation: Learn about the role of synthetic biology and advanced analytical tools in driving higher yields, streamlined timelines, and enhanced process control.
- Curia's Fermentation Expertise: Explore case studies showcasing Curia's proficiency in synthetic biology, strain enhancement, scaling processes, and downstream processing across various industries.
- The Promising Future: Gain insights into the future of biopharmaceutical fermentation, empowered by ongoing advances in molecular biology and engineering, offering sustainable alternatives for diverse applications.
